LUXTURNA™ (voretigene neparvovec-rzyl) logo LUXTURNA™ (voretigene neparvovec-rzyl) logo

NOW A REALITY: The first FDA-APPROVED gene therapy for a genetic disease

LUXTURNA is a prescription gene therapy product used for the treatment of patients with inherited retinal disease due to mutations in both copies of the RPE65 gene, which can only be confirmed through genetic testing. You must also have enough remaining cells in your retina (the thin layer of tissue in the back of your eyes) as determined by your healthcare professional.

Locate a Specialist

Use the Specialist Locator below to find a retinal specialist in your area of the United States who can discuss genetic testing for RPE65 mutations and may help determine if LUXTURNA is right for you.

I agree to the terms and conditions.